Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials

Vaccine

Volumn 34, Issue 13, 2016, Pages 1496-1503

  Diao, Wen qi ^a   Shen, Ning ^a   Yu, Pan xi ^b   Liu, Bei bei ^a   He, Bei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PLASTIC SURGERY HOSPITAL   (China)

Author keywords

23 Valent pneumococcal polysaccharide vaccine; Community acquired pneumonia; Efficacy; Immunocompetent; Meta analysis

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMIZED PATIENT; INCIDENCE; INFECTION CONTROL; META ANALYSIS; MORTALITY; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; ADULT; AGED; COMMUNITY-ACQUIRED INFECTIONS; HEALTH SERVICE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84960468240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.023     Document Type: Review

References (29)

1. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
2. Said M.A., Johnson H.L., Nonyane B.A., Deloria-Knoll M., O'Brien K.L., Andreo F., et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLOS ONE 2013, 8:e60273.
3. Debbache K., Varon E., Hicheri Y., Legrand P., Donay J.L., Ribaud P., et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis 2009, 15(9):865-868.
4. Kyaw M.H., Clarke S., Edwards G.F., Jones I.G., Campbell H. Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies. Epidemiol Infect 2000, 125:561-572.
5. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:Cd000422.
6. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J 2009, 180:48-58.
7. Bridges C.B., Coyne-Beasley T. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med 2014, 160:190.
8. CDC ACIP GRADE tables 2012 2012, US Department of Health and Human Services, CDC, Atlanta, GA, Available from: http://www.cdc.gov/vaccines/acip/recs/GRADE/pneumo-immuno-adults.html [accessed 10.10.12].
9. Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64:401-406.
10. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
11. Deeks JJ, Higgins JPT, Altman DG, editors (updated March 2011). Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0: The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org/.
12. Russell K.L., Baker C.I., Hansen C., Poland G.A., Ryan M.A., Merrill M.M., et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine 2015, 33:1182-1187.
13. Kawakami K., Ohkusa Y., Kuroki R., Tanaka T., Koyama K., Harada Y., et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan (Provisional abstract). Vaccine 2010, 7063-7069.
14. Maruyama T., Taguchi O., Niederman M.S., Morser J., Kobayashi H., Kobayashi T., et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ (Clin Res Ed) 2010, 340:c1004.
15. Alfageme I., Vazquez R., Reyes N., Munoz J., Fernandez A., Hernandez M., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006, 61:189-195.
16. Furumoto A., Ohkusa Y., Chen M., Kawakami K., Masaki H., Sueyasu Y., et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008, 26:4284-4289.
17. Steentoft J., Konradsen H.B., Hilskov J., Gislason G., Andersen J.R. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine 2006, 24:1408-1412.
18. Ortqvist A., Hedlund J., Burman L.A., Elbel E., Hofer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998, 351:399-403.
19. Honkanen P.O., Keistinen T., Miettinen L., Herva E., Sankilampi U., Laara E., et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999, 17:2493-2500.
20. Zhogolev S.D., Ogarkov P.I., Mel'nichenko P.I. [The prophylaxis of nonhospital pneumonia using 23-valent pneumococcus vaccine in the military collectives]. Voen Med Zh 2004, 325:35-43. 96.
21. Burton D.C., Flannery B., Bennett N.M., Farley M.M., Gershman K., Harrison L.H., et al. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Publ Health 2010, 100:1904-1911.
22. Li Y., Mukamel D.B. Racial disparities in receipt of influenza and pneumococcus vaccinations among US nursing-home residents. Am J Publ Health 2010, 100(Suppl. 1):S256-S262.
23. Gilchrist S.A., Nanni A., Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Publ Health 2012, 102:596-605.
24. Mahamat A., Daures J.P., de Wzieres B. Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study. Hum Vaccines Immunotherapeut 2013, 9:128-135.
25. Wilson K.C., Schunemann H.J. An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011, 183:1454-1462.
26. Jefferson T. Pneumococcal vaccines: confronting the confounders. Lancet 2009, 373:2008-2009.
27. Food and Drug Administration FDA expands use of Prevnar 13 vaccine for people ages 50 and older 2011, US Department of Health and Human Services; Food and Drug Administration, Silver Spring, MD, Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm.
28. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015, 372:1114-1125.
29. Active bacterial core surveillance (ABCs): emerging infections program network 2013, US Department of Health and Human Services, CDC, Atlanta, GA, [Unpublished data].